Giving Hope & Extending Life

To Whom It May Concern

Dear Sponsor 29 January 2019

KYLE NHLAPO ID 9903305070084 : FUNDING

Kyle Nhlapo is a 19 year old man who was diagnosed with osteosarcoma, a type of cancer that produces
immature bone. It is usually found at the end of long bones, and in Kyle’s case, around the knee. Most
people diagnosed with osteosarcoma are under the age of 25, and it is thought to occur more often in males
than females.

Kyle is now faced with the decision of amputation of his leg. Surgery cannot guarantee cure or remission
and chemo therapy has already been used and failed. His condition is now considered terminal unless the
cancer process is stopped and there is complete remission.

In conjunction with amputation, doctors have suggested that Kyle undergoes viro-immunotherapy using the
Rigvir® treatment protocol researched and developed in Latvia, a former state in Russia.

Rigvir® viro-immunotherapy is not available or registered in South Africa, but is only available from the
International Virotherapy Centre in Riga, Latvia. Fortunately, there is one doctor in South Africa who has
been trained in Latvia in the use of Rigvir® viro-immunotherapy for solid tumours (Stage 1 – 4) and who is
registered by the IVC in South Africa.

The doctor is Dr Steven Gunn, who is based in Pretoria and Sandton and who is registered by the IVC in
South Africa.

The treatment involves a series of injections according to a specific protocol for at least 3-6 months together
with adjunctive, supportive cancer therapy conducted on a daily and weekly basis for the duration of the
treatment at a dedicated clinic.

A special emergency Section 21 application has to be made to the Medicines Control Council at the
Department of Health for use of the product by Dr Gunn. Although the viro-immunotherapy cannot be
guaranteed to induce remission, or result in a complete cure, it has an outstanding record of efficacy and
safety, without causing any serious side effects, with numerous testimonials of success worldwide after
being administered to hundreds of patients over the past 14 years overseas.

There is no other equal treatment available in South Africa and this is Kyle’s last hope of achieving remission,
or extension of life with quality and dignity.

The cost of the Rigvir® and adjunctive supportive cancer therapy is R480,000.00 for 3 months or R790,000.00
for 6 months for full and intensive treatment. Medical Aids in South Africa do not cover this treatment.

LXM Humanitarian Foundation | 780 Petrick Street, Faerie Glen, Pretoria East, 0001 | +27 12 991 1464
Registration Number 2014/158072/08 PBO 930057564
www.lxmhf.co.za | info@lxmhf.co.za
 Giving Hope & Extending Life

In order for Kyle to have surgery in the private sector immediately, a further amount needs to be raised. His
family do not have medical aid to cover the costs. Sadly, the delay at State hospitals means that Kyle might
not be able to have this urgent and life-saving surgery.

Any benevolent sponsor, or funding organisation, or corporate, will be issued with a SARS IT12EI Tax
Exemption Certificate for tax deduction, by the LXM Humanitarian Foundation which is a fully registered
non-profit company (NPC) and public benefit organisation (PBO) with income tax exemption status.

Banking details for the LXM Foundation are :

Account Name LXM Humanitarian Foundation NPC
Bank ABSA
Branch Menlyn Maine
Branch Code 632005
Account No. 4084948082

Your contribution to help save Kyle’s life will be greatly appreciated.

Should you require any further information you are welcome contact me on +27 11 465 4514 or see our
website at www.lxmhf.co.za or email me at trisch@lxmhf.co.za.

Yours sincerely

Trisch Rosema
Chairperson

Tel : +27 11 4654514 / +27 71 413 2599

email trisch@lxmhf.co.za

LXM Humanitarian Foundation | 780 Petrick Street, Faerie Glen, Pretoria East, 0001 | +27 12 991 1464
Registration Number 2014/158072/08 PBO 930057564
www.lxmhf.co.za | info@lxmhf.co.za